Left Cardiac Sympathetic Denervation
Definition
Left cardiac sympathetic denervation (LCSD) is a surgical procedure involving thoracoscopic dissection of the lower two-thirds of the left stellate ganglion along with upper thoracic ganglia. It disrupts the primary sympathetic input to the heart, reducing catecholamine-driven arrhythmogenesis.
Key Concepts
-
Indication in LQTS: Recommended as an additional treatment when β-blockers are insufficient or intolerable. Post-LCSD QTc <500 ms predicts procedural effectiveness; persistent QTc >500 ms post-LCSD indicates elevated SCD risk and ICD candidacy. (sources/channelopathies-jaha-2025)
-
Indication in CPVT: Effective antiarrhythmic intervention in patients refractory to pharmacological treatment; reduces proarrhythmogenic sympathetic stimulation. (sources/channelopathies-jaha-2025)
-
LCSD is not always curative in CPVT; in cases of recurrence, right cardiac sympathetic denervation (RCSD) can be added to form complete bilateral sympathetic denervation. (sources/channelopathies-jaha-2025)
-
Complications: Ptosis, Horner syndrome, pneumothorax, neuropathic pain, emotional excitement, harlequin flushing after aerobic exercise. Despite these risks, LCSD has demonstrated improved quality of life in CPVT patients. (sources/channelopathies-jaha-2025)
-
LCSD addresses the sympathetic trigger for arrhythmias but does not correct the underlying ion channel or calcium-handling defect. (sources/channelopathies-jaha-2025)
-
ESC 2022 — Class I indication in LQTS (new): LCSD is indicated in symptomatic LQTS patients when: (a) ICD therapy is contraindicated or declined; OR (b) patient is on beta-blockers + genotype-specific therapies with an ICD AND still experiences multiple shocks or syncope due to VA. (sources/VA-SCD-ESC-2022)
-
ESC 2022 — Class IIa in CPVT (upgraded from IIb): LCSD should be considered when the combination of beta-blockers and flecainide at therapeutic dosage are either not effective, not tolerated, or contraindicated. (sources/VA-SCD-ESC-2022)
-
LCSD is also a Class IIa option in ES management when pharmacological therapy fails, particularly in CPVT or refractory SHD ES. (sources/VA-SCD-ESC-2022)
-
LCSD monotherapy — Mayo Clinic 20-year real-world data (n=60): 42 LQT1 (70%) and 18 LQT2 (30%); mean resting QTc 465±28 ms; mean age 30±14 years. Primary motivation was BB intolerance in 54 patients (90%). Only 3 patients (5%) experienced a non-lethal BCE post-LCSD; zero lethal events over follow-up. (sources/precision-lqts-tcm-2024, rating: high)
-
This confirms LCSD monotherapy as a safe and effective alternative when beta-blockers are intolerable, for select low-risk patients — an option not fully captured by international guidelines. Patients who desire to exercise without BB-related limitations are a key target group. (sources/precision-lqts-tcm-2024)
-
RCSD (right cardiac sympathetic denervation) in LQT3: Used in 5 LQT3 patients refractory to multiple therapies including LCSD + ICD. RCSD is always an incremental escalation step after LCSD failure, never as bilateral primary denervation or RCSD-first. (sources/precision-lqts-tcm-2024)
Contradictions / Open Questions
- LCSD as Class I in LQTS vs. Class IIa in CPVT — evidence parity questioned: ESC 2022 upgraded LCSD to Class I in LQTS and Class IIa in CPVT. The LQTS Class I upgrade is based on observational data from specialized centers without an RCT. The asymmetry in recommendation class between LQTS and CPVT reflects the relative sizes of available case series, not a qualitatively different evidence standard. (sources/VA-SCD-ESC-2022)
- RCSD addition in refractory CPVT — limited data: Right cardiac sympathetic denervation can be added to LCSD when bilateral complete denervation is needed in CPVT refractory to LCSD alone. The data supporting this escalation are limited to small case series; the rate of Horner syndrome, neuropathic pain, and other complications with bilateral sympathectomy is higher than LCSD alone. No comparative data versus LCSD alone exist. (sources/channelopathies-jaha-2025)
- Does not address the underlying defect: LCSD reduces sympathetic-driven arrhythmia triggers but does not correct the ion channel or Ca²⁺ handling defect. In gene therapy trials where structural correction is the goal, the relationship between LCSD and future gene therapy co-administration has not been studied. (sources/channelopathies-jaha-2025)
Connections
- Related to concepts/Torsades-de-Pointes
- Related to entities/Long-QT-Syndrome
- Related to entities/CPVT
- Related to concepts/Electrical-Storm